Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Not Recruiting

Trial ID: NCT00445146


The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.

Official Title

A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects

Stanford Investigator(s)

Philip Grant
Philip Grant

Asst Prof-Univ Med Line, Medicine - Infectious Diseases


Inclusion Criteria:

   - Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.

   - Males and females of childbearing potential must agree to utilize effective
   contraception methods.

   - Ability to understand and sign a written informed consent form.

Exclusion Criteria:

   - Females who are pregnant or breastfeeding.

   - Participation in any other clinical trial without prior approval from the Sponsor.

   - Any other clinical condition or prior therapy that, in the opinion of the
   investigator, would make the subject unsuitable for the study.

   - Subjects receiving ongoing therapy with contraindicated drugs.


drug: EVG

drug: RTV

drug: ARV regimen

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
(650) 723-2804